Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in ...

Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK). We have previously reported that activation of a ...

Chromosomal translocation fusion proteins contain a unique sequence at the junction of the fusion entities. The development of immunotherapies contingent on lymphocyte recognition of the junction ...

The chromosomal translocation [t (9;22)] associated oncogenic fusion protein BCR-ABL drives 90% of chronic myelogenous leukemia (CML). Approximately 9,000 CML diagnosis are expected for 2023. While ...

Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). A phase II study with ...

Chronic myeloid leukemia (CML) is a rare blood cancer that develops in the bone marrow. Karyotyping is a genetic technique doctors use to diagnose CML and choose more effective treatments. Karyotyping ...

CML is a malignant clonal disorder of hematopoietic stem cells that increases not only myeloid, but also erythroid cells and platelets in the peripheral blood and induces marked myeloid hyperplasia in ...

Chronic myeloid leukemia (CML) is a myeloproliferative disease that occurs because of a translocation between chromosomes 9 and 22 in hematopoietic stem cells. The switch results in a fusion of the ...

Please provide your email address to receive an email when new articles are posted on . Frontline nilotinib was associated with fewer treatment-emergent BCR-ABL mutations than imatinib in treatment of ...

Outcomes of Saudi Arabian Patients With Nasopharyngeal Cancer Treated With Primarily Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy We conducted a retrospective review of patients ...

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...